Newsroom

Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today...

read more +
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new...

read more +
Sight Sciences Appoints Erica Rogers to its Board of Directors

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the appointment of Erica Rogers...

read more +
International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚...

read more +
First International MIGS Data for the OMNI® Surgical System Presented at ESCRS

Sight Sciences announced clinical results from the first study of the OMNI® Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from...

read more +
Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million...

read more +
Sight Sciences Hires Leading Industry Executives to Drive Continued Growth

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that Jessica Holmes, Brian Regan...

read more +
First Subject Enrolled in large, multi-center pivotal trial to confirm safety and efficacy of TearCare® in the treatment of signs and symptoms of Dry Eye disease

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye, today announced the first subject has been enrolled...

read more +